Sapkota Nisha, Aryal Yubraj, Basnet Prasansa
Medicine, One Brooklyn Health-Interfaith Medical Center, New York, USA.
Hospital Medicine, Geisinger Medical Center, Danville, USA.
Cureus. 2025 Feb 15;17(2):e79072. doi: 10.7759/cureus.79072. eCollection 2025 Feb.
Granulomatosis with polyangiitis (GPA) is a rare autoimmune disease that causes inflammation in small and medium-sized blood vessels, affecting organs such as the lungs, kidneys, and sinuses. We report the case of a 66-year-old man with relapsing GPA. He first presented with sinus and ear symptoms, which were managed with steroids and other immunosuppressive drugs. After many years of remission, he relapsed with nasal congestion, nosebleeds, and lung nodules. During his latest flare, he was treated with high-dose prednisone, rituximab, and avacopan, a new oral drug that blocks the C5a receptor. Avacopan helped reduce inflammation and allowed for a significant decrease in steroid use. The patient's rapid improvement supports the role of avacopan as a steroid-sparing agent in GPA management, offering a promising way to reduce the harmful side effects of long-term steroid therapy.
肉芽肿性多血管炎(GPA)是一种罕见的自身免疫性疾病,可导致中小血管炎症,影响肺部、肾脏和鼻窦等器官。我们报告一例66岁复发性GPA男性病例。他最初表现为鼻窦和耳部症状,接受了类固醇和其他免疫抑制药物治疗。经过多年缓解后,他再次出现鼻塞、鼻出血和肺结节复发。在他最近一次病情发作期间,接受了高剂量泼尼松、利妥昔单抗和阿伐可泮(一种阻断C5a受体的新型口服药物)治疗。阿伐可泮有助于减轻炎症,并使类固醇使用量显著减少。患者的快速改善支持了阿伐可泮在GPA治疗中作为类固醇节约剂的作用,为减少长期类固醇治疗的有害副作用提供了一种有前景的方法。